166 related articles for article (PubMed ID: 11811789)
21. Soluble glycoprotein 130 (gp130) attenuates OSM- and LIF-induced cartilage proteoglycan catabolism.
Hui W; Bell M; Carroll G
Cytokine; 2000 Feb; 12(2):151-5. PubMed ID: 10671300
[TBL] [Abstract][Full Text] [Related]
22. Oncostatin M and leukemia inhibitory factor trigger overlapping and different signals through partially shared receptor complexes.
Thoma B; Bird TA; Friend DJ; Gearing DP; Dower SK
J Biol Chem; 1994 Feb; 269(8):6215-22. PubMed ID: 8119965
[TBL] [Abstract][Full Text] [Related]
23. Influence of subunit combinations on signaling by receptors for oncostatin M, leukemia inhibitory factor, and interleukin-6.
Kuropatwinski KK; De Imus C; Gearing D; Baumann H; Mosley B
J Biol Chem; 1997 Jun; 272(24):15135-44. PubMed ID: 9182534
[TBL] [Abstract][Full Text] [Related]
24. Activation of Jak-Stat and MAPK2 pathways by oncostatin M leads to growth inhibition of human glioma cells.
Halfter H; Friedrich M; Postert C; Ringelstein EB; Stögbauer F
Mol Cell Biol Res Commun; 1999 May; 1(2):109-16. PubMed ID: 10356359
[TBL] [Abstract][Full Text] [Related]
25. Expression of interleukin (IL)-11 receptor by the human endometrium in vivo and effects of IL-11, IL-6 and LIF on the production of MMP and cytokines by human endometrial cells in vitro.
Cork BA; Tuckerman EM; Li TC; Laird SM
Mol Hum Reprod; 2002 Sep; 8(9):841-8. PubMed ID: 12200462
[TBL] [Abstract][Full Text] [Related]
26. Dual oncostatin M (OSM) receptors. Cloning and characterization of an alternative signaling subunit conferring OSM-specific receptor activation.
Mosley B; De Imus C; Friend D; Boiani N; Thoma B; Park LS; Cosman D
J Biol Chem; 1996 Dec; 271(51):32635-43. PubMed ID: 8999038
[TBL] [Abstract][Full Text] [Related]
27. Regulation of the type II oncostatin M receptor expression in lung-derived epithelial cells.
Cichy J; Rose-John S; Puré E
FEBS Lett; 1998 Jun; 429(3):412-6. PubMed ID: 9662460
[TBL] [Abstract][Full Text] [Related]
28. Menstrual cycle-specific inhibition of endometrial stromal cell proliferation by oncostatin M.
Ohata Y; Harada T; Fujii A; Yoshida S; Iwabe T; Terakawa N
Mol Hum Reprod; 2001 Jul; 7(7):665-70. PubMed ID: 11420390
[TBL] [Abstract][Full Text] [Related]
29. Leukemia inhibitory factor (LIF), cardiotrophin-1, and oncostatin M share structural binding determinants in the immunoglobulin-like domain of LIF receptor.
Plun-Favreau H; Perret D; Diveu C; Froger J; Chevalier S; Lelièvre E; Gascan H; Chabbert M
J Biol Chem; 2003 Jul; 278(29):27169-79. PubMed ID: 12707269
[TBL] [Abstract][Full Text] [Related]
30. Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components.
Stahl N; Boulton TG; Farruggella T; Ip NY; Davis S; Witthuhn BA; Quelle FW; Silvennoinen O; Barbieri G; Pellegrini S
Science; 1994 Jan; 263(5143):92-5. PubMed ID: 8272873
[TBL] [Abstract][Full Text] [Related]
31. Cytotoxicity of paclitaxel or cisplatin on carcinoma cell lines is not inhibited by leukemia inhibitory factor (LIF).
O'Flaherty E; Cook W; Boyd J; Grant SL; Kurek J; Begley CG
Growth Factors; 2002 Sep; 20(3):141-5. PubMed ID: 12519017
[TBL] [Abstract][Full Text] [Related]
32. Oncostatin M synergises with house dust mite proteases to induce the production of PGE(2) from cultured lung epithelial cells.
Knight DA; Asokananthan N; Watkins DN; Misso NL; Thompson PJ; Stewart GA
Br J Pharmacol; 2000 Oct; 131(3):465-72. PubMed ID: 11015296
[TBL] [Abstract][Full Text] [Related]
33. Differential inhibition of IL-6-type cytokine-induced STAT activation by PMA.
Terstegen L; Maassen BG; Radtke S; Behrmann I; Schaper F; Heinrich PC; Graeve L; Gatsios P
FEBS Lett; 2000 Jul; 478(1-2):100-4. PubMed ID: 10922477
[TBL] [Abstract][Full Text] [Related]
34. The IL-6 family cytokines, interleukin-6, interleukin-11, oncostatin M, and leukemia inhibitory factor, enhance mast cell growth through fibroblast-dependent pathway in mice.
Gyotoku E; Morita E; Kameyoshi Y; Hiragun T; Yamamoto S; Hide M
Arch Dermatol Res; 2001 Nov; 293(10):508-14. PubMed ID: 11820727
[TBL] [Abstract][Full Text] [Related]
35. The soluble interleukin-6 receptor.
Rose-John S; Ehlers M; Grötzinger J; Müllberg J
Ann N Y Acad Sci; 1995 Jul; 762():207-20; discussion 220-1. PubMed ID: 7668529
[No Abstract] [Full Text] [Related]
36. Expression of oncostatin M and its receptors in normal and cirrhotic human liver.
Znoyko I; Sohara N; Spicer SS; Trojanowska M; Reuben A
J Hepatol; 2005 Nov; 43(5):893-900. PubMed ID: 16169119
[TBL] [Abstract][Full Text] [Related]
37. Proliferative responses and binding properties of hematopoietic cells transfected with low-affinity receptors for leukemia inhibitory factor, oncostatin M, and ciliary neurotrophic factor.
Gearing DP; Ziegler SF; Comeau MR; Friend D; Thoma B; Cosman D; Park L; Mosley B
Proc Natl Acad Sci U S A; 1994 Feb; 91(3):1119-23. PubMed ID: 8302840
[TBL] [Abstract][Full Text] [Related]
38. Leukemia inhibitory factor binds to human breast cancer cells and stimulates their proliferation.
Estrov Z; Samal B; Lapushin R; Kellokumpu-Lehtinen P; Sahin AA; Kurzrock R; Talpaz M; Aggarwal BB
J Interferon Cytokine Res; 1995 Oct; 15(10):905-13. PubMed ID: 8564713
[TBL] [Abstract][Full Text] [Related]
39. Oncostatin M: a new potent inhibitor of iodine metabolism inhibits thyroid peroxidase gene expression but not DNA synthesis in porcine thyroid cells in culture.
Isozaki O; Tsushima T; Miyakawa M; Emoto N; Demura H; Arai M; Sato-Nozoe Y
Thyroid; 1997 Feb; 7(1):71-7. PubMed ID: 9086575
[TBL] [Abstract][Full Text] [Related]
40. Oncostatin M binds the high-affinity leukemia inhibitory factor receptor.
Gearing DP; Bruce AG
New Biol; 1992 Jan; 4(1):61-5. PubMed ID: 1536831
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
